LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Non-Invasive Melanoma Test Ushers in New Era in Skin Cancer Detection

By LabMedica International staff writers
Posted on 25 Jan 2023
Image: Smart Stickers are changing the way melanoma is detected (Photo courtesy of DermTech)
Image: Smart Stickers are changing the way melanoma is detected (Photo courtesy of DermTech)

Skin cancer overall is the most common form of cancer with melanoma being the third most common and also the most aggressive form of skin cancer. Now, an innovative test painlessly collect cells from the skin and applies precision genomics to diagnose melanoma accurately and at the earliest curable stage.

The DermTech Melanoma Test from DermTech (La Jolla, CA, USA) is a non-invasive genomic test that enables early detection of melanoma by identifying the presence of genomic markers found in melanoma – often much earlier than the current biopsy pathway. The Smart Sticker gently lifts skin cells containing genomic material from the surface of the skin while the adhesive on the sticker stores and preserves the skin cells so that it can be sent to DermTech’s Gene Lab for examination.

Using a proprietary precision genomic test, DermTech’s genomic analysis looks for melanoma at the gene level, 10,000 times closer than even a microscope. The test detects LINC00518 and PRAME using RT-PCR which makes billions of copies of these genes. An additional test can also be conducted to identify the presence of TERT gene driver mutations using a DNA sequencing technique. Positive results for LINC00518, PRAME, or TERT correlate with the presence of melanoma. If the genomic markers found in melanoma are present, this will typically result in a biopsy of the spot. If the biomarkers are not detected (meaning negative results), there could be a greater than 99% probability that the mole being tested is not melanoma.

The Smart Sticker uses a specially formulated adhesive to gently lift skin cells from the surface of the skin, but it is not strong enough to cause pain, bleeding or damage to the site. The DermTech Melanoma Test is not a replacement for a biopsy. If the genomic markers exist, then the doctor can use this information to choose the best path forward for the patient’s treatment. The DermTech Melanoma Test is rather a step before a biopsy that can see genomic markers linked to melanoma far earlier than the traditional biopsy pathway can.

Related Links:
DermTech

New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more